



**HAL**  
open science

## ColVI-myopathies: where do we stand, where do we go?

Allamand V, Laura Briñas, Pascale Richard, Tanya Stojkovic, Susana Quijano-Roy, Gisèle Bonne

### ► To cite this version:

Allamand V, Laura Briñas, Pascale Richard, Tanya Stojkovic, Susana Quijano-Roy, et al.. ColVI-myopathies: where do we stand, where do we go?. *Skeletal Muscle*, 2011, 1 (1), pp.30. 10.1186/2044-5040-1-30 . inserm-00630240

**HAL Id: inserm-00630240**


**<https://inserm.hal.science/inserm-00630240>**

Submitted on 7 Oct 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Skeletal Muscle



## ColVI myopathies: where do we stand, where do we go?

Allamand *et al.*

REVIEW

Open Access

# ColVI myopathies: where do we stand, where do we go?

Valérie Allamand<sup>1,2,3,4\*</sup>, Laura Briñas<sup>1,2,3,4</sup>, Pascale Richard<sup>5</sup>, Tanya Stojkovic<sup>1,2,3,4,6</sup>, Susana Quijano-Roy<sup>7</sup> and Gisèle Bonne<sup>1,2,3,4,5</sup>

## Abstract

Collagen VI myopathies, caused by mutations in the genes encoding collagen type VI (ColVI), represent a clinical continuum with Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) at each end of the spectrum, and less well-defined intermediate phenotypes in between. ColVI myopathies also share common features with other disorders associated with prominent muscle contractures, making differential diagnosis difficult. This group of disorders, under-recognized for a long time, has aroused much interest over the past decade, with important advances made in understanding its molecular pathogenesis. Indeed, numerous mutations have now been reported in the *COL6A1*, *COL6A2* and *COL6A3* genes, a large proportion of which are *de novo* and exert dominant-negative effects. Genotype-phenotype correlations have also started to emerge, which reflect the various pathogenic mechanisms at play in these disorders: dominant *de novo* exon splicing that enables the synthesis and secretion of mutant tetramers and homozygous nonsense mutations that lead to premature termination of translation and complete loss of function are associated with early-onset, severe phenotypes. In this review, we present the current state of diagnosis and research in the field of ColVI myopathies. The past decade has provided significant advances, with the identification of altered cellular functions in animal models of ColVI myopathies and in patient samples. In particular, mitochondrial dysfunction and a defect in the autophagic clearance system of skeletal muscle have recently been reported, thereby opening potential therapeutic avenues.

## Review

### Collagen VI: an important component of connective tissues


Collagens are major constituents of the extracellular matrix (ECM), and are found in most connective tissues. They provide structural and mechanical stability to tissues, but they also play crucial roles in cell-ECM interactions through various receptors [1]. In particular, collagen type VI (ColVI), an important component of skeletal muscle ECM, is involved in maintaining tissue integrity by providing a structural link between different constituents of connective-tissue basement membranes (for example, collagen types I and IV, biglycan, and decorin) and cells [2-15] (Figure 1). In addition to its structural role, ColVI supports adhesion, spreading and migration of cells, and cell survival, as discussed later in this review.

ColVI is a heterotrimeric molecule composed of three individual  $\alpha$ (VI) chains that display a similar structure, with a triple helical domain characterized by the repetition of the Gly-X-Y amino acid sequence, flanked by globular domains homologous to von Willebrand factor A domains [16,17]. In addition to the well-known  $\alpha$ 1(VI),  $\alpha$ 2(VI) and  $\alpha$ 3(VI) chains encoded in human by the *COL6A1*, *COL6A2* (located head-to-tail on chromosome 21q22.3), and *COL6A3* (on chromosome 2q37) genes [18], three novel chains,  $\alpha$ 4(VI),  $\alpha$ 5(VI) and  $\alpha$ 6(VI), have recently been identified [19,20]. These chains have high structural homology to the  $\alpha$ 3(VI) chain. In humans, the *COL6A4*, *COL6A5* and *COL6A6* genes are all located on chromosome 3q22.1, with the *COL6A4* gene being split by a chromosome break and thus not coding for a protein [19-21]. The murine orthologs of these genes are organized in tandem on chromosome 9 (*Col6a4*, *Col6a5* and *Col6a6*) and encode the  $\alpha$ 4(VI),  $\alpha$ 5(VI) and  $\alpha$ 6(VI) chains. The expression pattern of the three novel chains differs between mice and humans, and also between fetal and adult tissues [19,20].

\* Correspondence: v.allamand@institut-myologie.org

<sup>1</sup>Inserm, U974, Paris, France

Full list of author information is available at the end of the article



Importantly, in the context of ColVI myopathies, the  $\alpha 6$  (VI) chain is the only one expressed at high levels in human skeletal muscle, at higher levels in fetal than adult tissue [19]. In skin, a detailed analysis of the expression of the human  $\alpha 5$ (VI) and  $\alpha 6$ (VI) chains revealed that both chains are expressed, albeit differently, and that they are variably altered in tissues from patients with mutations in the *COL6A1*, *COL6A2* and *COL6A3* genes [22]. Interestingly, the *COL6A5* gene had previously been reported as associated with atopic dermatitis under the name *COL29A1* [23], but this association has recently been questioned [24,25]. The knee osteoarthritis susceptibility locus *DVWA* was shown to correspond to the 5' part of the split *COL6A4* gene [21].

Although largely ubiquitous, the expression of ColVI seems to be finely regulated in different cell types and tissues, as shown for the murine *Col6a1* gene. The identification of a transcriptional enhancer located in the 5'-flanking sequence of the gene points to a collaborative crosstalk between myogenic and mesenchymal/endomyxial cells, enabling transcription of ColV in muscle connective tissue [26-28].

The  $\alpha 1$ (VI),  $\alpha 2$ (VI) and  $\alpha 3$ (VI) chains assemble intracellularly as monomers (1:1:1 ratio), from their C-terminal ends, and subsequently form dimers (two anti-parallel, overlapping monomers) and tetramers (four monomers) that are stabilized by disulfide bonds between cysteine residues of the three chains [29-34]. ColVI chains are subjected to extensive post-translational modifications such as hydroxylation of lysine and proline residues [35], and glycosylation of hydroxylysines, which have been shown to be essential for the tetramerization and further secretion of ColVI [36,37]. Upon secretion, tetramers are further aligned end to end as microfibrils in the extracellular space, with a characteristic beaded appearance [33] (Figure 1). To date, somewhat contradictory results have been obtained regarding the possible assembly of the newly characterized  $\alpha$ (VI) polypeptides with the  $\alpha 1$ (VI),  $\alpha 2$ (VI) chains. In transfection experiments, only  $\alpha 4$ (VI) appeared to have this ability [19], whereas in mouse muscle, all three were reported to do so [20]. Whether and how these additional chains may fit in the pathogenesis of ColVI myopathies remains unresolved to date, and needs to be addressed more comprehensively. To date, in our cohort of patients, no pathogenic mutations have been found by sequencing of the *COL6A5* and *COL6A6* genes in patients without mutations in the *COL6A1-3* genes (V. Allamand, data not shown).

#### Clinical phenotypes of collagen VI myopathies


The etiological definition of ColVI myopathies as a specific condition has evolved over the years with the blurring of boundaries between two disorders, initially

described separately but now recognized as the extreme ends of a continuous clinical spectrum [38,39] (Figure 2). The severe endpoint of this spectrum corresponds to Ullrich congenital muscular dystrophy (UCMD, OMIM 254090; <http://www.ncbi.nlm.nih.gov/omim>), described in 1930 as 'congenital atonic-sclerotic muscular dystrophy', emphasizing its early onset and the presence of proximal joint contractures associated with a striking distal hyperlaxity [40,41]. Orthopedic deformities (joint contractures, scoliosis) and respiratory impairment with diaphragmatic failure generally develop within the first decade of life, and may be life-threatening. Arrest of motor milestones with no acquisition of walking ability is seen in a subset of patients, but most children are able to walk, and show later progression of muscle weakness with loss of ambulation around 10 years of age, and a requirement for mechanical ventilation in late childhood or young adulthood [42,43].

At the other end of the spectrum is the milder form Bethlem myopathy (BM, OMIM 158810), described in 1976, which begins in the first or second decade, although a neonatal history may be recognized, characterized by early contractures of finger flexors, wrist, elbows and ankles [44,45]. Respiratory failure and distal hyperlaxity are usually absent or are milder than in UCMD, although the latter may not be so uncommon in very young children with BM. The course is usually slow, with most of the patients remaining ambulatory. However, progression of muscle weakness occurs often in the fifth decade, resulting in about 50% of patients requiring walking aids or a wheelchair [46]. Intermediate phenotypes have been described, and named 'mild UCMD' or 'severe BM', thereby reinforcing the notion of clinical overlap between Ullrich and Bethlem phenotypes [38,39].

Skin features such as follicular hyperkeratosis and hypertrophic scars or keloid formation are common [38,39,42,43,47-49]. Other common findings include normal cognitive abilities, normal or only slightly raised serum creatine kinase (CK) levels, and absence of cardiac phenotype. Two other conditions that fall within the spectrum of ColVI myopathies have been documented: autosomal dominant limb-girdle muscular dystrophy (LGMD) (in three families) and, more recently, autosomal recessive myosclerosis myopathy (OMIM 255600) (in one family) [50,51].

The prevalences of UCMD and BM in northern England has recently been reported as 0.13 and 0.77 per 100,000, respectively, amounting collectively to 0.9 per 100,000 [52]. UCMD seems to be the second most common type of congenital muscular dystrophy (CMD) in Europe (behind laminin  $\alpha 2$  chain deficiency; OMIM 607855) and also in Japan (behind Fukuyama congenital muscular dystrophy; OMIM 253800, [53]) and Australia



(behind  $\alpha$ -dystroglycan glycosylation defects; [54]). In the cohort from northern England, BM emerges as the fourth most common myopathy behind myotonic dystrophy (OMIM 160900), facio-scapulo-humeral muscular dystrophy (OMIM 158900) and Duchenne/Becker muscular dystrophy (OMIM 310200 and 300376) [52].

#### Differential diagnosis of ColVI-related myopathies

With the most prominent clinical presentation of ColVI myopathies being muscle weakness and contractures, associated with variable degrees of hyperlaxity, an important difficulty lies in defining boundaries and contiguities, with the possible differential diagnosis including congenital myopathies, Emery-Dreifuss muscular dystrophy (EDMD; OMIM 181350), LGMD, rigid spine muscular dystrophies, and other diseases of connective tissues such as Ehlers-Danlos syndrome

[55-57]. Imaging techniques, such as computed tomography or magnetic resonance imaging (MRI) of muscle, are now recognized as very helpful in the diagnostic approach of muscle disease, because there are specific patterns of muscle involvement in each of these contractile myopathies as reported for EDMD with *LMNA* mutations [58], muscular dystrophies with rigidity of the spine [59], and ColVI myopathies [58,60,61]. From these studies, the typical pattern of muscle involvement in ColVI myopathies is now considered to be constituted by a diffuse, concentric hypodensity of the thigh muscles with relative sparing of the sartorius, gracilis and adductor longus muscles. The vasti muscles are the most affected muscles. In addition, a peculiar central area of abnormal signal is seen within the rectus femoris, initially referred to as a 'central shadow' [62].

In the context of the differential diagnosis, the absence of raised CK levels, the lack of a cardiac phenotype, and the presence of a specific MRI pattern are strongly suggestive of a ColVI myopathy.

### Molecular diagnosis and genetics

In light of the clinical variability and the overlapping presentation with other muscular disorders, a definite diagnosis can only be made after the identification of pathogenic mutations in one of the *COL6A* genes, which to date are restricted to *COL6A1*, *COL6A2* and *COL6A3*. However, the large size (106 coding exons in total corresponding to 150 kb of genomic DNA) of these genes makes routine molecular diagnostics costly and time-consuming. The road to this 'holy grail' of diagnosis is thus often lengthy and full of pitfalls, and relies on a combination of clinical, biochemical and molecular findings.

Historically, muscle biopsies were the routine and primary step undertaken for diagnostic purposes, and double immunostaining with a basement-membrane marker enabled recognition of ColVI deficiency in patients with UCMD [63], but not in patients with BM. The current diagnostic method of determining ColVI involvement is primarily based on immunocytochemistry of cultured skin fibroblasts, but this analysis is only available in a limited number of laboratories to date. A number of antibodies recognizing human ColVI are now commercially available and may be used for such techniques; in particular, the refined protocol proposed by Hicks *et al.* [64], using a polyclonal antibody raised against mature ColVI from human placenta, has better sensitivity, especially in fibroblast cultures from patients with BM (Figure 3). The absence or alteration of ColVI secretion in cultured fibroblasts, associated with clinical symptoms compatible with a diagnosis of ColVI myopathy, certainly warrants further genetic analysis.


Over the past decade, the development of genetic studies has demonstrated the heterogeneity and complexity of the molecular mechanisms at play in ColVI myopathies. An autosomal recessive pattern of inheritance was initially thought to be involved in UCMD, and linkage analysis led to the identification of mutations in the *COL6A2* and *COL6A3* genes [65-67]. However, numerous dominant *de novo* mutations have now been shown to be involved, accounting for more than 50% of the mutations causing UCMD [38,39,42,68]. Similarly, autosomal dominant mutations were first identified in the *COL6A1* and *COL6A2* genes in families with BM, suggesting that BM was mostly familial and inherited as an autosomal dominant disease [69], although rare *de novo* mutations and autosomal recessive mutations have now been reported [70-73]. To date, over 200 mutations have been identified in these genes, mostly distributed

in the *COL6A1* and *COL6A2* genes. The most common types of mutations are point mutations, and mutations leading to premature termination codons (PTCs) and exon skipping (Figure 4). Among the former, missense changes affecting glycine residues in the triple helical domains of the corresponding proteins are the most common, and are often dominant *de novo*. Because these changes affect crucial amino acids within the collagenous domains, they hamper triple-helix formation [74-77]. Splice mutations resulting in in-frame exon skipping are generally dominant *de novo* mutations, and exons 16 of *COL6A3* and 14 of *COL6A1* seem to be preferentially affected, leading to UCMD or BM phenotypes, respectively [53,75,78-83]. Nonsense mutations and small deletions or insertions inducing PTCs within the coding frame are mostly inherited as recessive mutations, and lead to loss of function of the protein [42,53,68,75,76,79-92]. These mutations are responsible for most UCMD phenotypes. Nevertheless, it should be noted that genotype-phenotype correlations are very difficult to identify.

It has recently been shown that all types of mutations alter transcript levels, and that in the case of PTC-bearing transcripts, which are specifically degraded *via* the nonsense-mediated mRNA decay (NMD [93,94]) pathway, quantification of the three *COL6A* mRNAs is a helpful tool to pinpoint the mutated gene, thereby facilitating these cumbersome molecular analyses [42]. The NMD-induced degradation of PTC-bearing transcripts may also, at least in part, explain why the parents of patients with UCMD who themselves harbor recessive mutations are asymptomatic; their heterozygous status sustains the expression of 50% of the 'normal' protein, thereby leading to a 'functional loss of heterozygosity'. The study by Briñas and collaborators also provided some genotype-phenotype correlations in a cohort of patients with early-onset ColVI myopathy, showing that recessive mutations leading to PTC were associated with severe phenotypes [42]. Genetic studies are further complicated by a possibly variable penetrance as reported by Peat *et al.* [89].

Finally, the highly polymorphic nature of the *COL6A* genes makes it difficult to definitely assign pathogenicity to some variants, especially missense ones that do not affect glycine residues within the triple-helix domains of the proteins. In addition, these 'polymorphisms' may very well play a role in the extreme clinical variability of these conditions, particularly in patients carrying identical mutations but presenting with variable severity.

The types of mutations identified also reflect the methods used in laboratories performing these analyses (for example, sequencing of genomic DNA or of the coding sequences on cDNA), but the emergence of high-throughput methods (arrays) is likely to allow the




identification of as yet unknown or under-recognized pathogenic mechanisms, such as large gene rearrangements, or promoter or deep intronic mutations, as recently illustrated in two reports [95,96].

#### Animal models and pathophysiology

Limited access to muscle biopsies hinders extensive investigations of the specific cellular mechanisms leading to the development of the muscle pathology, and *in vitro/ex vivo* cellular systems only partially reproduce the complexity of the tissue. The development of the first animal model of ColVI deficiency in 1998, engineered by invalidating the *Col6a1* gene in mice, has

proven central to understanding the cellular pathways involved in these diseases. Homozygous animals were reported to develop a mild myopathic phenotype, and were initially described as a model of BM [97]. Interestingly, the diaphragm was the most affected muscle, with signs of necrosis evidenced by uptake of Evan's blue dye [97]. Subsequently, a latent mitochondrial dysfunction accompanied by ultrastructural alterations of mitochondria and the sarcoplasmic reticulum, resulting in spontaneous apoptosis, was found in about one-third of muscle fibers [98]. Reduced contractile strength of the diaphragm and other muscle groups was also reported in *Col6a1*<sup>-/-</sup> mice in this initial study [98]. The maximal






isometric tension generated by ColVI-deficient skinned fibers from gastrocnemius was found to be reduced in a recent report; however, using a protocol of eccentric contractions *in vivo*, no muscle force drop was found, indicating that the lack of ColVI does not impair myofibrillar function [99]. Importantly, mitochondrial dysfunction was also reported in cultured muscle cells from patients and could be reversed by cyclosporin (Cs)A, an immunosuppressive drug that prevents the opening of the mitochondrial permeability transition pore through binding to cyclophilin D, and also inhibits the phosphatase calcineurin [100,101]. Another *in vitro* study

showed that patients-derived skin fibroblasts behave differently from myoblasts in that respect, and also questioned the specificity of this mitochondrial dysfunction [102], warranting further studies on the matter.

A role for cell survival had previously been proposed for ColVI because it was shown to prevent anti- $\alpha 1$  integrin-mediated apoptosis and trigger the downregulation of bax, a pro-apoptotic molecule [103,104].

Recently, a study of the autophagic process in muscles of *Col6a1* knockout mice revealed that autophagy was not induced efficiently [105]. The ensuing defective autophagy provides the link between the previously



**Figure 5 Current pathological hypotheses and therapeutic targets.** The currently known cascade of main events leading to myofiber degeneration in ColVI-deficient skeletal muscle is shown. Mitochondrial dysfunction (due in part to the defective permeability transition pore (PTP) opening) triggers an energetic imbalance with the increased levels of phosphorylated adenosine monophosphate-activated protein kinase (p-AMPK), Ca<sup>2+</sup> overload and the production of reactive oxygen species (ROS). Lack of autophagy induction exacerbates the cellular dysfunction because defective mitochondria and proteins (such as p62 aggregates) are not cleared from the cytoplasm. Together, these defects lead to increased apoptosis. Potential therapeutic interventions are indicated in green.

described mitochondrial dysfunction and myofiber degeneration, as abnormal organelles and molecules cannot be efficiently cleared from the cell. This study further showed that the forced induction of autophagy, either by dietary restriction or by treatment with rapamycin or CsA, ameliorated the phenotype of the *Col6a1*<sup>-/-</sup> mice (Figure 5). A similar alteration of autophagy was also detected in muscle biopsies derived from nine patients with UCMD or BM [105]. These data thus provide a basis for novel therapeutic targets to promote the elimination of defective organelles in ColVI-deficient skeletal muscle.

Morpholino-mediated knock-down of the *col6a1* and *col6a3* genes in zebrafish embryos showed that collagen VI deficiency significantly impairs muscle development and function [106]. Increased apoptosis, partially prevented by CsA treatment, was also described in the zebrafish morphants [106]. As in other instances, perturbation of muscle components leads to a more severe phenotype in zebrafish than in mouse models, which may in part be due to intrinsic differences in muscle development in these species, especially in terms of timing. Zebrafish models have emerged as major *in vivo* models of neuromuscular disorders, and seem to be particularly well suited for whole-organism screens for potential pharmacological treatments, as recently illustrated in zebrafish models of Duchenne muscular dystrophy [107].

### Therapeutic intervention

To date, no curative treatment exists for these disorders, and most patients rely on supportive treatment of symptoms, usually involving orthopedic (spinal deformations, contractures) and respiratory complications [108].

The unveiling of mitochondrial dysfunction led to an open pilot trial in five patients with UCMD or BM treated orally with CsA for 1 month [109]. This study reported normalization of the mitochondrial dysfunction and decrease of apoptosis of muscle cells following this short-term treatment [110,111]. Longer treatment (up to 2 years) had some beneficial effect on muscle function in these patients but did not prevent progression of the disease in the children [38]. Debio-025 (D-MeAla3Et-Val4-cyclosporin; DebioPharm) prevents the inappropriate opening of the mitochondrial permeability transition pore (PTP) without interfering with calcineurin [112], and was shown to restore mitochondrial function in cultured muscle cells of patients [100] and in *Col6a1*<sup>-/-</sup> mice [113]. Debio-025 is currently being tested in a phase II clinical trial in patients with chronic hepatitis C. Another anti-apoptotic pharmacological agent that is being investigated in the context of ColVI myopathies is Omigapil (N-(dibenz(b, f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine maleate; Santhera Pharmaceuticals),

a chemical derivative of (-)-deprenyl, which was shown to reduce GAPDH-Siah1-mediated apoptosis in a mouse model of laminin  $\alpha 2$  chain deficiency [114].

It should be noted that translating some of this research from animal models to patients represents a challenging task, particularly because, to date, these drugs have not been approved for use in children, the patient population with the most severe forms of ColVI myopathies. In addition, there is concern about these therapeutic approaches because of the pleiotropic, and potentially harmful, consequences of anti-apoptotic and/or pro-autophagy treatments. Furthermore, such approaches aiming at modulating downstream pathways would not address the primary defect in these disorders, that is, lack of ColVI in the connective tissue, and would thus need to be continually administered. For the sake of discussion, several alternative, and not necessarily exclusive, therapeutic avenues that would sustain re-expression of ColVI may be envisioned. These approaches may consist of gene-based therapies, such as vector delivery of ColVI-coding sequence, and antisense inhibition of mutant transcripts exerting dominant-negative effects [96]. Additionally, as nonsense mutations leading to PTCs are often associated with early-onset, severe phenotypes [42], pharmacological approaches aiming to 'force' translation of PTCs (a phenomenon known as 'translational readthrough' [115]) may prove beneficial for a subset of patients carrying these types of mutations. However, the complex assembly process and regulation of ColVI may prove challenging and may limit the realistic options to be investigated.

### Conclusions

The past decade of research on neuromuscular disorders has proven very exciting, and has seen ColVI myopathies emerge as an important set of disorders, rather under-recognized until recently. Many challenges remain despite the tremendous advances in the understanding of their genetic, biochemical and pathophysiological bases. It is hoped that the decade(s) to come will see the development of safe and efficient therapies for these disorders. Consequently, as for other rare diseases, the scientific community, and patient organizations, and patients and their families have become increasingly aware of the need for databases, both clinical and genetic, to facilitate recruitment of patients for upcoming clinical trials.

### List of abbreviations used

BM: Bethlem myopathy; ColVI: collagen type VI; COL6A: gene(s) encoding the alpha chain(s) of collagen VI; CsA: cyclosporin A; DAPI: 4',6-diamidino-2-phenylindole; EDMD: Emery-Dreifuss muscular dystrophy; EDS: Ehlers-Danlos syndrome; LMNA: gene encoding lamin A/C; MDC1A: congenital muscular

dystrophy with laminin  $\alpha 2$  chain deficiency; PTP: permeability transition pore; MRI: magnetic resonance imaging; PTC: premature termination codon; ROS: reactive oxygen species; *SEPN1*: gene encoding selenoprotein N; *TNXB*: gene encoding tenascin-X; UCMD: Ullrich congenital muscular dystrophy

#### Acknowledgements

We thank Corine Gartioux and Céline Ledeuil for excellent technical skills. This study was funded by the Institut National de la Santé et de la Recherche Médicale (Inserm), Association Française contre les Myopathies (AFM), UPMC Université Paris 06, Centre National de la Recherche Scientifique (CNRS), Assistance Publique-Hôpitaux de Paris (AP-HP). We apologize to all colleagues who might have not been cited in this review due to space limitations.

#### Author details

<sup>1</sup>Inserm, U974, Paris, France. <sup>2</sup>CNRS, UMR7215, Paris, France. <sup>3</sup>UPMC Univ Paris 06 UMR76, IFR14, Paris, France. <sup>4</sup>Institut de Myologie, Paris, France. <sup>5</sup>AP-HP, Groupe Hospitalier Pitié-Salpêtrière, UF Cardiogénétique et Myogénétique, Service de Biochimie Métabolique, Paris, France. <sup>6</sup>Centre de Référence Neuromusculaire Paris-Est, Institut de Myologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. <sup>7</sup>AP-HP, Service de Pédiatrie, Centre de Référence Maladies Neuromusculaires (GNMH) Hôpital Raymond Poincaré, Garches, France.

#### Authors' contributions

All authors contributed to the writing of this manuscript. All authors read and approved the final manuscript.

#### Authors' information

Valérie Allamand holds a PhD in Human Genetics, and currently leads a group focusing on ColVI myopathies in the research unit directed by Thomas Voit. In 2009, she co-organized, with Drs Kate Bushby and Luciano Merlini, the 166th ENMC International Workshop on Collagen Type VI-Related Myopathies (22-24 May 2009, Naarden, The Netherlands). She is the genetic curator of the UMD-COL6 databases, developed in the context of the Treat-NMD European network of excellence.

Laura Briñas obtained her PhD in Molecular Biology. She joined the Institut de Myologie in September 2006 as a post-doctoral fellow, and has been involved in the molecular analysis of mutations in the genes encoding collagen VI and the dissection of their cellular consequences.

Susana Quijano-Roy is a child neurologist with previous medical training in La Paz Hospital (Madrid, Spain) and Boston Children's Hospital (USA). She has held a clinical practice since 2001 at Garches Neuromuscular Reference Center (GNMH), and leads the pediatric EMG laboratory at Necker Enfants Hospital, Paris. She obtained her PhD in 2004 with a study on congenital muscular dystrophies (CMDs). She is part of the international expert group that is currently defining diagnosis, standards of care and natural history of CMDs and establishing outcome measures for future therapeutic trials.

Tanya Stojkovic is a medical doctor, specialized in neurophysiology and neuromuscular disorders. She has worked in the neuromuscular clinical unit directed by Professor Eymard since 2006 (Pitié-Salpêtrière, Institut de Myologie, Paris, France). She is involved, as a clinician, in the diagnosis of neuromuscular disorders. She has a special interest in ColVI-related myopathies.

Pascale Richard holds a PharmD, Graduation from Medical Biologist and a PhD in molecular genetics. She is head of the 'Functional Unit of Molecular Cardiogenetics and Myogenetics' at Pitié-Salpêtrière Hospital in Paris, where she developed a functional unit focused on the molecular diagnosis of cardiomyopathies and congenital and progressive myopathies in close collaboration with the research units. This unit constitutes the only laboratory in France where the genetic diagnosis of ColVI myopathies is proposed.

Gisèle Bonne holds a PhD in developmental physiology, followed by a post-doctoral training in human genetics. She currently leads the team 'Genetics and Pathophysiology of Neuromuscular Disorders' in the research unit directed by Thomas Voit at the Institut de Myologie in Paris. Her research group focuses on neuromuscular disorders caused by mutations in the lamin A/C gene.

#### Competing interests

The authors declare that they have no competing interests.

Received: 24 March 2011 Accepted: 23 September 2011

Published: 23 September 2011

#### References

- Leitinger B, Hohenester E: Mammalian collagen receptors. *Matrix Biol* 2007, **26**:146-155.
- Bidanset D, Guidry C, Rosenberg L, Choi H, Timpl R, Hook M: Binding of the proteoglycan decorin to collagen type VI. *J Biol Chem* 1992, **267**:5250-5256.
- Bonaldo P, Russo V, Bucciotti F, Doliana R, Colombatti A: Structural and functional features of the alpha 3 chain indicate a bridging role for chicken collagen VI in connective tissues. *Biochemistry* 1990, **29**:1245-1254.
- Burg MA, Tillet E, Timpl R, Stallcup WB: Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules. *J Biol Chem* 1996, **271**:26110-26116.
- Doane KJ, Yang G, Birk DE: Corneal cell-matrix interactions: type VI collagen promotes adhesion and spreading of corneal fibroblasts. *Exp Cell Res* 1992, **200**:490-499.
- Heino J: The collagen family members as cell adhesion proteins. *BioEssays* 2007, **29**:1001-1010.
- Keene D, Engvall E, Glanville R: Ultrastructure of type VI collagen in human skin and cartilage suggests an anchoring function for this filamentous network. *J Cell Biol* 1988, **107**:1995-2006.
- Kiely CM, Whittaker SP, Grant ME, Shuttleworth CA: Type VI collagen microfibrils: evidence for a structural association with hyaluronan. *J Cell Biol* 1992, **118**:979-990.
- Kuo H-J, Maslen CL, Keene DR, Glanville RW: Type VI collagen anchors endothelial basement membranes by interacting with Type IV collagen. *J Biol Chem* 1997, **272**:26522-26529.
- McDevitt CA, Marcelino J, Tucker L: Interaction of intact type VI collagen with hyaluronan. *FEBS Letters* 1991, **294**:167-170.
- Pfaff M, Aumailley M, Specks U, Knolle J, Zerwes HG, Timpl R: Integrin and Arg-Gly-Asp dependence of cell adhesion to the native and unfolded triple helix of collagen type VI. *Exp Cell Res* 1993, **206**:167-176.
- Specks U, Mayer U, Nischt R, Spissinger T, Mann K, Timpl R, Engel J, Chu ML: Structure of recombinant N-terminal globule of type VI collagen alpha 3 chain and its binding to heparin and hyaluronan. *Embo J* 1992, **11**:4281-4290.
- Takahashi T, Cho HI, Kublin CL, Cintron C: Keratan sulfate and dermatan sulfate proteoglycans associate with type VI collagen in fetal rabbit cornea. *J Histochem Cytochem* 1993, **41**:1447-1457.
- Tillet E, Ruggiero F, Nishiyama A, Stallcup WB: The membrane-spanning proteoglycan NG2 binds to collagens V and VI through the central nonglobular domain of its core protein. *J Biol Chem* 1997, **272**:10769-10776.
- Wiberg C, Klatt AR, Wagener R, Paulsson M, Bateman JF, Heinegard D, Morgelin M: Complexes of matrilin-1 and biglycan or decorin connect collagen VI microfibrils to both collagen II and aggrecan. *J Biol Chem* 2003, **278**:37698-37704.
- Chu ML, Pan TC, Conway D, Kuo HJ, Glanville RW, Timpl R, Mann K, Deutzmann R: Sequence analysis of alpha 1(VI) and alpha 2(VI) chains of human type VI collagen reveals internal triplication of globular domains similar to the A domains of von Willebrand factor and two alpha 2(VI) chain variants that differ in the carboxy terminus. *EMBO J* 1989, **8**:1939-1946.
- Chu ML, Zhang RZ, Pan TC, Stokes D, Conway D, Kuo HJ, Glanville R, Mayer U, Mann K, Deutzmann R, Timpl R: Mosaic structure of globular domains in the human type VI collagen alpha 3 chain: similarity to von Willebrand factor, fibronectin, actin, salivary proteins and aprotinin type protease inhibitors. *EMBO J* 1990, **9**:385-393.
- Weil D, Mattei MG, Passage E, N'Guyen VC, Pribula-Conway D, Mann K, Deutzmann R, Timpl R, Chu ML: Cloning and chromosomal localization of human genes encoding the three chains of type VI collagen. *Am J Hum Genet* 1988, **42**:435-445.
- Fitzgerald J, Rich C, Zhou FH, Hansen U: Three novel collagen VI Chains, {alpha}4(VI), {alpha}5(VI), and {alpha}6(VI). *J Biol Chem* 2008, **283**:20170-20180.
- Gara SK, Grumati P, Urciuolo A, Bonaldo P, Kobbe B, Koch M, Paulsson M, Wagener R: Three novel collagen vi chains with high homology to the {alpha}3 chain. *J Biol Chem* 2008, **283**:10658-10670.

21. Wagener R, Gara SK, Kobbe B, Paulsson M, Zaucke F: **The knee osteoarthritis susceptibility locus DVWA on chromosome 3p24.3 is the 5' part of the split COL6A4 gene.** *Matrix Biol* 2009, **28**:307-310.
22. Sabatelli P, Gara SK, Grumati P, Urciuolo A, Gualandi F, Curci R, Squarzone S, Zamparelli A, Martoni E, Merlini L, Paulsson M, Bonaldo P, Wagener R: **Expression of the collagen VI [alpha]5 and [alpha]6 chains in normal human skin and in skin of patients with collagen VI-related myopathies.** *J Invest Dermatol* 2010, **131**:99-107.
23. Söderhäll C, Marenholz I, Kerscher T, Rüschemdorf F, Esparza-Gordillo J, Worm M, Gruber C, Mayr G, Albrecht M, Rohde K, Schulz H, Wahn U, Hubner N, Lee YA: **Variants in a novel epidermal collagen gene (col29a1) are associated with atopic dermatitis.** *PLoS Biology* 2007, **5**:e242.
24. Castro-Giner F, Bustamante M, Ramon Gonzalez J, Kogevinas M, Jarvis D, Heinrich J, Anto J-M, Wjst M, Estivill X, de Cid R: **A pooling-based genome-wide analysis identifies new potential candidate genes for atopy in the European Community Respiratory Health Survey (ECRHS).** *BMC Medical Genetics* 2009, **10**:128.
25. Esparza-Gordillo J, Weidinger S, Folster-Holst R, Bauerfeind A, Ruschendorf F, Patone G, Rohde K, Marenholz I, Schulz F, Kerscher T, Hubner U, Wahn S, Schreiber A, Franke R, Vogler S, Heath H, Baurecht N, Novak E, Rodriguez T, Illig M-A, Lee-Kirsch A, Ciechanowicz M, Kurek T, Piskackova M, Macek Y-A, Lee Ruether A: **A common variant on chromosome 11q13 is associated with atopic dermatitis.** *Nat Genet* 2009, **41**:596-601.
26. Braghetta P, Fabbro C, Piccolo S, Marulli D, Bonaldo P, Volpin D, Bressan GM: **Distinct regions control transcriptional activation of the alpha1(VI) collagen promoter in different tissues of transgenic mice.** *J Cell Biol* 1996, **135**:1163-1177.
27. Braghetta P, Ferrari A, Fabbro C, Bizzotto D, Volpin D, Bonaldo P, Bressan GM: **An enhancer required for transcription of the Col6a1 gene in muscle connective tissue is induced by signals released from muscle cells.** *Exp Cell Res* 2008, **314**:3508-3518.
28. Girotto D, Fabbro C, Braghetta P, Vitale P, Volpin D, Bressan GM: **Analysis of transcription of the Col6a1 gene in a specific set of tissues suggests a new variant of enhancer region.** *J Biol Chem* 2000, **275**:17381-17390.
29. Baldock C, Sherratt MJ, Shuttleworth CA, Kielty CM: **The supramolecular organization of collagen VI microfibrils.** *J Mol Biol* 2003, **330**:297-307.
30. Ball S, Bella J, Kielty C, Shuttleworth A: **Structural basis of type VI collagen dimer formation.** *J Biol Chem* 2003, **278**:15326-15332.
31. Chu M, Conway D, Pan T, Baldwin C, Mann K, Deutzmann R, Timpl R: **Amino acid sequence of the triple-helical domain of human collagen type VI.** *J Biol Chem* 1988, **263**:18601-18606.
32. Engel J, Furthmayr H, Odermatt E, Von Der Mark H, Aumailley M, Fleischmajer R, Timpl R: **Structure and macromolecular organization of type VI collagen.** *Annals of the New York Academy of Sciences* 1985, **460**:25-37.
33. Engvall E, Hessel H, Klier G: **Molecular assembly, secretion, and matrix deposition of type VI collagen.** *J Cell Biol* 1986, **102**:703-710.
34. Furthmayr H, Wiedemann H, Timpl R, Odermatt E, Engel J: **Electron-microscopical approach to a structural model of intima collagen.** *Biochem J* 1983, **211**:303-311.
35. Myllyharju J, Kivirikko KI: **Collagens, modifying enzymes and their mutations in humans, flies and worms.** *Trends in Genet* 2004, **20**:33-43.
36. Risteli M, Ruotsalainen H, Salo AM, Sormunen R, Sipilä L, Baker NL, Lamande SR, Vimpri-Kauppinen L, Myllylä R: **Reduction of Lysyl hydroxylase 3 causes deleterious changes in the deposition and organization of extracellular Matrix.** *J Biol Chem* 2009, **284**:28204-28211.
37. Sipilä L, Ruotsalainen H, Sormunen R, Baker NL, Lamande SR, Vapola M, Wang C, Sado Y, Aszodi A, Myllylä R: **Secretion and assembly of type IV and VI collagens depend on glycosylation of hydroxylysines.** *J Biol Chem* 2007, **282**:33381-33388.
38. Allamand V, Merlini L, Bushby K: **166th ENMC International Workshop on Collagen type VI-related Myopathies, 22-24 May 2009, Naarden, The Netherlands.** *Neuromusc Disord* 2010, **20**:346-354.
39. Lampe AK, Bushby KMD: **Collagen VI related muscle disorders.** *J Med Genet* 2005, **42**:673-685.
40. Nonaka I, Une Y, Ishihara T, Miyoshino S, Nakashima T, Sugita H: **A clinical and histological study of Ullrich's disease (congenital atonic-sclerotic muscular dystrophy).** *Neuroped* 1981, **12**:197-208.
41. Ullrich O: **Kongenitale, atonisch-sklerotische Muskeldystrophie, ein weiteres Typus der heredodegenerativen Erkrankungen des neuromuskulären Systems.** *Z Gesamte Neurol Psychiat* 1930, **126**:171-201.
42. Briñas L, Richard P, Quijano-Roy S, Gartioux C, Ledeuil C, Makri S, Ferreira A, Maugenre S, Topaloglu H, Haliloglu G, Péniisson-Besnier I, Jeannet P-Y, Merlini L, Navarro C, Toutain A, Chaigne D, Desguerre I, de Die-Smulders C, Dunand M, Echenne B, Eymard B, Kuntzer T, Maincent K, Mayer M, Plessis G, Rivier F, Roelens F, Stojkovic T, Taratuto A, Lubieniecki F, et al: **Early onset collagen VI myopathies: genetic and clinical correlations.** *Annals of Neurol* 2010, **68**:511-520.
43. Nadeau A, Kinali M, Main M, Jimenez-Mallebrera C, Aloysius A, Clement E, North B, Manzur AY, Robb SA, Mercuri E, Muntoni F: **Natural history of Ullrich congenital muscular dystrophy.** *Neurology* 2009, **73**:25-31.
44. Bethlem J, Van Wijngaarden GK: **Benign myopathy with autosomal inheritance: a report of three pedigrees.** *Brain* 1976, **99**:91-100.
45. De Visser M, van der Kooij AJ, Jobsis GJ: **Bethlem myopathy.** In *Myology*. Edited by: Franzini-Amstrong AGEaC. New York: McGraw-Hill; 2004:1135-1146.
46. Jobsis GJ, Boers JM, Barth PG, de Visser M: **Bethlem myopathy: a slowly progressive congenital muscular dystrophy with contractures.** *Brain* 1999, **122**:649-655.
47. Kirschner J, Hausser I, Zou Y, Schreiber G, Christen HJ, Brown SC, Anton-Lamprecht I, Muntoni F, Hanefeld F, Bonnemann CG: **Ullrich congenital muscular dystrophy: connective tissue abnormalities in the skin support overlap with Ehlers-Danlos syndromes.** *Am J Med Genet A* 2005, **132**:296-301.
48. Nalini A, Gayathri N: **Bethlem myopathy: A study of two families.** *Neurol India* 2010, **58**:665-666.
49. Pepe G, Bertini E, Bonaldo P, Bushby K, Giusti B, de Visser M, Guicheney P, Lattanzi G, Merlini L, Muntoni F, Nishino I, Nonaka I, Ben Yaou R, Sabatelli P, Sewry C, Topaloglu H, van der Kooij A: **Bethlem myopathy (BETHLEM) and Ullrich scleroatonic muscular dystrophy: 100th ENMC International Workshop, 23-24 November 2001, Naarden, The Netherlands.** *Neuromusc Disord* 2002, **12**:984-993.
50. Merlini L, Martoni E, Grumati P, Sabatelli P, Squarzone S, Urciuolo A, Ferlini A, Gualandi F, Bonaldo P: **Autosomal recessive myosclerosis myopathy is a collagen VI disorder.** *Neurology* 2008, **71**:1245-1253.
51. Scacheri PC, Gillanders EM, Subramony SH, Vedanarayanan V, Crowe CA, Thakore N, Bingler M, Hoffman EP: **Novel mutations in collagen VI genes: expansion of the Bethlem myopathy phenotype.** *Neurology* 2002, **58**:593-602.
52. Norwood FLM, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V: **Prevalence of genetic muscle disease in northern England: in-depth analysis of a muscle clinic population.** *Brain* 2009, **132**:3175-3186.
53. Okada M, Kawahara G, Noguchi S, Sugie K, Murayama K, Nonaka I, Hayashi YK, Nishino I: **Primary collagen VI deficiency is the second most common congenital muscular dystrophy in Japan.** *Neurology* 2007, **69**:1035-1042.
54. Peat RA, Smith JM, Compton AG, Baker NL, Pace RA, Burkin DJ, Kaufman SJ, Lamande SR, North KN: **Diagnosis and etiology of congenital muscular dystrophy.** *Neurology* 2008, **71**:312-321.
55. Bateman JF, Boot-Handford RP, Lamande SR: **Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations.** *Nat Rev Genet* 2009, **10**:173-183.
56. Voermans NC, Bönnemann CG, Huijij PA, Hamel BC, van Kuppevelt TH, de Haan A, Schalkwijk J, van Engelen BG, Jenniskens GJ: **Clinical and molecular overlap between myopathies and inherited connective tissue diseases.** *Neuromusc Disord* 2008, **18**:843-856.
57. Voermans NC, van Alfen N, Pillen S, Lammens M, Schalkwijk J, Zwarts MJ, van Rooij IA, Hamel BC, van Engelen BG: **Neuromuscular involvement in various types of Ehlers-Danlos syndrome.** *Annals of Neurol* 2009, **65**:687-697.
58. Deconinck N, Dion E, Ben Yaou R, Ferreira A, Eymard B, Briñas L, Payan C, Voit T, Guicheney P, Richard P, Allamand V, Bonne G, Stojkovic T: **Differentiating Emery-Dreifuss muscular dystrophy and collagen VI-related myopathies using a specific CT scanner pattern.** *Neuromusc Disord* 2010, **20**:517-523.
59. Mercuri E, Clements E, Offiah A, Pichiecchio A, Vasco G, Bianco F, Berardinelli A, Manzur A, Pane M, Messina S, Gualandi F, Ricci E, Rutherford M, Muntoni F: **Muscle magnetic resonance imaging involvement in muscular dystrophies with rigidity of the spine.** *Annals of Neurol* 2010, **67**:201-208.
60. Mercuri E, Cini C, Pichiecchio A, Allsop J, Counsell S, Zolkipli Z, Messina S, Kinali M, Brown SC, Jimenez C: **Muscle magnetic resonance imaging in**

- patients with congenital muscular dystrophy and Ullrich phenotype. *Neuromusc Disord* 2003, **13**:554-558.
61. Mercuri E, Lampe A, Allsop J, Knight R, Pane M, Bonnemann C, Flanigan K, Lapini I, Bushby K, Pepe G, Muntoni F: **Muscle MRI in Ullrich congenital muscular dystrophy and Bethlem myopathy.** *Neuromusc Disord* 2005, **15**:303-310.
  62. Bonnemann C, Brockmann K, Hanefeld F: **Muscle ultrasound in Bethlem myopathy.** *Neuroped* 2003, **34**:335-336.
  63. Kawahara G, Okada M, Morone N, Ibarra CA, Nonaka I, Noguchi S, Hayashi YK, Nishino I: **Reduced cell anchorage may cause sarcolemma-specific collagen VI deficiency in Ullrich disease.** *Neurology* 2007, **69**:1043-1049.
  64. Hicks D, Lampe AK, Barresi R, Charlton R, Fiorillo C, Bonnemann CG, Hudson J, Sutton R, Lochmuller H, Straub V, Bushby K: **A refined diagnostic algorithm for Bethlem myopathy.** *Neurology* 2008, **70**:1192-1199.
  65. Camacho Vanegas O, Bertini E, Zhang R-Z, Petrini S, Minosse C, Sabatelli P, Giusti B, Chu M-F, Pepe G: **Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI.** *Proc Natl Acad Sci USA* 2001, **98**:7516-7521.
  66. Demir E, Ferreiro A, Sabatelli P, Allamand V, Makri S, Echenne B, Maraldi NM, Merlini L, Topaloglu H, Guicheney P: **Collagen VI status and clinical severity in Ullrich congenital muscular dystrophy: phenotype analysis of 11 families linked to the COL6 loci.** *Neuroped* 2004, **35**:103-112.
  67. Demir E, Sabatelli P, Allamand V, Ferreiro A, Moghadasszadeh B, Makrelouf M, Topaloglu H, Echenne B, Merlini L, Guicheney P: **Mutations in COL6A3 cause severe and mild phenotypes of Ullrich congenital muscular dystrophy.** *Am J Hum Genet* 2002, **70**:1446-1458.
  68. Baker NL, Morgelin M, Peat R, Goemans N, North KN, Bateman JF, Lamande SR: **Dominant collagen VI mutations are a common cause of Ullrich congenital muscular dystrophy.** *Hum Mol Genet* 2005, **14**:279-293.
  69. Jobsis GJ, Keizers H, Vreijling JP, de Visser M, Speer MC, Wolterman RA, Baas F, Bolhuis PA: **Type VI collagen mutations in Bethlem myopathy, an autosomal dominant myopathy with contractures.** *Nat Genet* 1996, **14**:113-115.
  70. Foley AR, Hu Y, Zou Y, Columbus A, Shoffner J, Dunn DM, Weiss RB, Bonnemann CG: **Autosomal recessive inheritance of classic Bethlem myopathy.** *Neuromusc Disord* 2009, **19**:813-817.
  71. Gualandi F, Urciuolo A, Martoni E, Sabatelli P, Squarzone S, Bovolenta M, Messina S, Mercuri E, Franchella A, Ferlini A, Bonaldo P, Merlini L: **Autosomal recessive Bethlem myopathy.** *Neurology* 2009, **73**:1883-1891.
  72. Pepe G, Bertini E, Giusti B, Brunelli T, Comeglio P, Saitta B, Merlini L, Chu ML, Federici G, Abbate R: **A novel de novo mutation in the triple helix of the COL6A3 gene in a two-generation Italian family affected by Bethlem myopathy. A diagnostic approach in the mutations' screening of type VI collagen.** *Neuromusc Disord* 1999, **9**:264-271.
  73. Pepe G, de Visser M, Bertini E, Bushby K, Vanegas OC, Chu ML, Lattanzi G, Merlini L, Muntoni F, Urtizbera A: **Bethlem myopathy (BETHLEM) 86th ENMC international workshop, 10-11 November 2000, Naarden, The Netherlands.** *Neuromusc Disord* 2002, **12**:296-305.
  74. Lamandé SR, Morgelin M, Selan C, Jobsis GJ, Baas F, Bateman JF: **Kinked collagen VI tetramers and reduced microfibril formation as a result of Bethlem myopathy and introduced triple helical glycine mutations.** *J Biol Chem* 2002, **277**:1949-1956.
  75. Lamandé SR, Shields KA, Kornberg AJ, Shield LK, Bateman JF: **Bethlem myopathy and engineered collagen VI triple helical deletions prevent intracellular multimer assembly and protein secretion.** *J Biol Chem* 1999, **274**:21817-21822.
  76. Pace R, Peat R, Baker N, Zamurs L, Mörgelein M, Irving M, Adams N, Bateman J, Mowat D, Smith N, Lamont P, Moore S, Mathews K, North K, Lamandé S: **Collagen VI glycine mutations: perturbed assembly and a spectrum of clinical severity.** *Annals of Neurol* 2008, **64**:294-303.
  77. Sasaki T, Hohenester E, Zhang RZ, Gotta S, Speer MC, Tandan R, Timpl R, Chu ML: **A Bethlem myopathy Gly to Glu mutation in the von Willebrand factor A domain N2 of the collagen alpha3(VI) chain interferes with protein folding.** *Faseb J* 2000, **14**:761-768.
  78. Baker NL, Mörgelein M, Pace RA, Peat RA, Adams NE, Gardner RJM, Rowland LP, Miller G, De Jonghe P, Ceulemans B, Hannibal MC, Edwards M, Thompson EM, Jacobson R, Quinlivan RCM, Aftimos S, Kornberg AJ, North KN, Bateman JF, Lamandé SR: **Molecular consequences of dominant Bethlem myopathy collagen VI mutations.** *Annals of Neurol* 2007, **9999**:NA.
  79. Lampe AK, Dunn DM, von Niederhausern AC, Hamil C, Aoyagi A, Laval SH, Marie SK, Chu M-L, Swoboda K, Muntoni F, Bonnemann CG, Flanigan KM, Bushby KMD, Weiss RB: **Automated genomic sequence analysis of the three collagen VI genes: applications to Ullrich congenital muscular dystrophy and Bethlem myopathy.** *J Med Genet* 2005, **42**:108-120.
  80. Lampe AK, Zou Y, Sudano D, O'Brien KK, Hicks D, Laval SH, Charlton R, Jimenez-Mallebrera C, Zhang RZ, Finkel RS, Tennekoon G, Schreiber G, van der Knaap MS, Marks H, Straub V, Flanigan KM, Chu ML, Muntoni F, Bushby KMD, Bonnemann CG: **Exon skipping mutations in collagen VI are common and are predictive for severity and inheritance.** *Human Mut* 2008, **29**:809-822.
  81. Luciola S, Giusti B, Mercuri E, Camacho Vanegas O, Lucarini L, Pietroni V, Urtizbera J-A, Ben Yaou R, de Visser M, van der Kooij AJ, Bonnemann CG, Iannaccone ST, Merlini L, Bushby K, Muntoni F, Bertini E, Chu ML, Pepe G: **Detection of common and private mutations in the COL6A1 gene of patients with Bethlem myopathy.** *Neurology* 2005, **64**:1931-1937.
  82. Pan T, Zhang R, Sudano D, Marie S, Bonnemann C, Chu M: **New molecular mechanism for Ullrich congenital muscular dystrophy: a heterozygous in-frame deletion in the COL6A1 gene causes a severe phenotype.** *Am J Hum Genet* 2003, **73**:355-369.
  83. Pepe G, Giusti B, Bertini E, Brunelli T, Saitta B, Comeglio P, Bolognese A, Merlini L, Federici G, Abbate R, Chu M-L: **A Heterozygous splice site mutation in COL6A1 leading to an in-frame deletion of the [alpha]1(VI) collagen chain in an Italian family affected by Bethlem myopathy.** *Biochem Biophys Res Com* 1999, **258**:802-807.
  84. Giusti B, Lucarini L, Pietroni V, Luciola S, Bandinelli B, Petrini S, Gartioux C, Talim B, Roelens F, Merlini L, Topaloglu H, Bertini E, Guicheney P, Pepe G: **Dominant and recessive COL6A1 mutations in Ullrich scleroatonic muscular dystrophy.** *Ann Neurol* 2005, **58**:400-410.
  85. Jimenez-Mallebrera C, Maioli MA, Kim J, Brown SC, Feng L, Lampe AK, Bushby K, Hicks D, Flanigan KM, Bonnemann C, Sewry CA, Muntoni F: **A comparative analysis of collagen VI production in muscle, skin and fibroblasts from 14 Ullrich congenital muscular dystrophy patients with dominant and recessive COL6A mutations.** *Neuromusc Disorders* 2006, **16**:571-582.
  86. Lamandé SR, Sigalas E, Pan TC, Chu ML, Dziadek M, Timpl R, Bateman JF: **The role of the alpha3(VI) chain in collagen VI assembly. Expression of an alpha3(VI) chain lacking N-terminal modules N10-N7 restores collagen VI assembly, secretion, and matrix deposition in an alpha3(VI)-deficient cell line.** *J Biol Chem* 1998, **273**:7423-7430.
  87. Lucarini L, Giusti B, Zhang R-Z, Pan TC, Jimenez-Mallebrera C, Mercuri E, Muntoni F, Pepe G, Chu M-L: **A homozygous COL6A2 intron mutation causes in-frame triple-helical deletion and nonsense-mediated mRNA decay in a patient with Ullrich congenital muscular dystrophy.** *Hum Genet* 2005, **117**:460-466.
  88. Martoni E, Urciuolo A, Sabatelli P, Fabris M, Bovolenta M, Neri M, Grumati P, D'Amico A, Pane M, Mercuri E, Bertini E, Merlini L, Bonaldo P, Ferlini A, Gualandi F: **Identification and characterization of novel collagen VI non-canonical splicing mutations causing ullrich congenital muscular dystrophy.** *Human Mut* 2009, **30**:E662-E672.
  89. Peat RA, Baker NL, Jones KJ, North KN, Lamandé SR: **Variable penetrance of COL6A1 null mutations: Implications for prenatal diagnosis and genetic counselling in Ullrich congenital muscular dystrophy families.** *Neuromusc Disorders* 2007, **17**:547-557.
  90. Pepe G, Lucarini L, Zhang RZ, Pan T, Giusti B, Quijano-Roy S, Gartioux C, Bushby KM, Guicheney P, Chu ML: **COL6A1 genomic deletions in Bethlem myopathy and Ullrich muscular dystrophy.** *Ann Neurol* 2006, **59**:190-195.
  91. Tooley LD, Zamurs LK, Beecher N, Baker NL, Peat RA, Adams NE, Bateman JF, North KN, Baldock C, Lamandé SR: **Collagen VI microfibril formation is abolished by an alpha(VI) von Willebrand factor A-domain mutation in a patient with Ullrich congenital muscular dystrophy.** *J Biol Chem* 2010.
  92. Zhang R-Z, Zou Y, Pan T-C, Markova D, Fertala A, Hu Y, Squarzone S, Reed UC, Marie SKN, Bonnemann CG, Chu M-L: **Recessive COL6A2 C-globular missense mutations in Ullrich congenital muscular dystrophy.** *J Biol Chem* 2010, **285**:10005-10015.
  93. Chang YF, Imam JS, Wilkinson MF: **The nonsense-mediated decay RNA surveillance pathway.** *Annual Review of Biochemistry* 2007, **76**:51-74.
  94. Maquat LE, Carmichael GG: **Quality control of mRNA function.** *Cell* 2001, **104**:173-176.

95. Bovolenta M, Neri M, Martoni E, Urciuolo A, Sabatelli P, Fabris M, Grumati P, Mercuri E, Bertini E, Merlini L, Bonaldo P, Ferlini A, Gualandi F: **Identification of a deep intronic mutation in the COL6A2 gene by a novel custom oligonucleotide CGH array designed to explore allelic and genetic heterogeneity in collagen VI-related myopathies.** *BMC Medical Genetics* 2010, **11**:44.
96. Foley AR, Hu Y, Zou Y, Yang M, Medne L, Leach M, Conlin LK, Spinner N, Shaikh TH, Falk M, Neumeyer AM, Bliss L, Tseng BS, Winder TL, Bonnemann CG: **Large genomic deletions: A novel cause of Ullrich congenital muscular dystrophy.** *Annals of Neurol* 2011, **69**:206-211.
97. Bonaldo P, Braghetta P, Zanetti M, Piccolo S, Volpin D, Bressan GM: **Collagen VI deficiency induces early onset myopathy in the mouse: an animal model for Bethlem myopathy.** *Hum Mol Genet* 1998, **7**:2135-2140.
98. Irwin W, Bergamin N, Sabatelli P, Reggiani C, Megighian A, Merlini L, Braghetta P, Columbaro M, Volpin D, Bressan G, Bernardi P, Bonaldo P: **Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency.** *Nat Genet* 2003, **35**:367-371.
99. Blaauw B, Agatea L, Toniolo L, Canato M, Quarta M, Dyar KA, Danieli-Betto D, Betto R, Schiaffino S, Reggiani C: **Eccentric contractions lead to myofibrillar dysfunction in muscular dystrophy.** *J Applied Physiology* 2010, **108**:105-111.
100. Angelin A, Tiepolo T, Sabatelli P, Grumati P, Bergamin N, Golfieri C, Mattioli E, Gualandi F, Ferlini A, Merlini L, Maraldi NM, Bonaldo P, Bernardi P: **Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins.** *Proc Natl Acad Sci USA* 2007, **104**:991-996.
101. Bernardi P, Bonaldo P: **Dysfunction of mitochondria and sarcoplasmic reticulum in the pathogenesis of collagen VI muscular dystrophies.** *Annals of the New York Academy of Sciences* 2008, **1147**:303-311.
102. Hicks D, Lampe AK, Laval SH, Allamand V, Jimenez-Mallebrera C, Walter MC, Muntoni F, Quijano-Roy S, Richard P, Straub V, Lochmuller H, Bushby KMD: **Cyclosporine. A treatment for Ullrich congenital muscular dystrophy: a cellular study of mitochondrial dysfunction and its rescue.** *Brain* 2009, **132**:147-155.
103. Howell SJ, Doane KJ: **Type VI collagen increases cell survival and prevents anti-[beta]1 integrin-mediated apoptosis.** *Exp Cell Res* 1998, **241**:230-241.
104. Ruhl M, Sahin E, Johannsen M, Somasundaram R, Manski D, Riecken EO, Schuppan D: **Soluble collagen VI drives serum-starved fibroblasts through S Phase and prevents apoptosis via down-regulation of Bax.** *J Biol Chem* 1999, **274**:34361-34368.
105. Grumati P, Coletto L, Sabatelli P, Cescon M, Angelin A, Bertaglia E, Blaauw B, Urciuolo A, Tiepolo T, Merlini L, Maraldi NM, Bernardi P, Sandri M, Bonaldo P: **Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration.** *Nat Med* 2010, **16**:1313-1320.
106. Telfer WR, Busta AS, Bonnemann CG, Feldman EL, Dowling JJ: **Zebrafish models of collagen VI-related myopathies.** *Hum Mol Genet* 2010, **19**:2433-2444.
107. Kawahara G, Karpf JA, Myers JA, Alexander MS, Guyon JR, Kunkel LM: **Drug screening in a zebrafish model of Duchenne muscular dystrophy.** *Proc Natl Acad Sci USA* 2011, **108**:5331-5336.
108. Wang CH, Bonnemann CG, Rutkowski A, Sejersen T, Bellini J, Battista V, Florence JM, Schara U, Schuler PM, Wahbi K, Aloysius A, Bash RO, Bérout C, Bertini E, Bushby K, Cohn RD, Connolly AM, Deconinck N, Desguerre I, Eagle M, Estournet-Mathiaud B, Ferreiro A, Fujak A, Goemans N, Iannaccone ST, Jouinot P, Main M, Melacini P, Mueller-Felber W, Muntoni F, et al: **Consensus statement on standard of care for congenital muscular dystrophies.** *J Child Neurol* 2010, **25**:1559-1581.
109. Merlini L, Angelin A, Tiepolo T, Braghetta P, Sabatelli P, Zamparelli A, Ferlini A, Maraldi NM, Bonaldo P, Bernardi P: **Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies.** *Proc Natl Acad Sci USA* 2008, **105**:5225-5229.
110. Maraldi NM, Sabatelli P, Columbaro M, Zamparelli A, Manzoli FA, Bernardi P, Bonaldo P, Merlini L: **Collagen VI myopathies: From the animal model to the clinical trial.** *Advances in Enzyme Regulation* 2009, **49**:197-211.
111. Merlini L, Bernardi P: **Therapy of collagen VI-related myopathies (Bethlem and Ullrich).** *Neurotherapeutics* 2008, **5**:613-618.
112. Hansson MJ, Mattiasson G, Månsson R, Karlsson J, Keep MF, Waldmeier P, Ruegg UT, Dumont J-M, Besseghir K, Elmér E: **The Nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria.** *Journal of Bioenergetics and Biomembranes* 2004, **36**:407-413.
113. Tiepolo T, Angelin A, Palma E, Sabatelli P, Merlini L, Nicolosi L, Finetti F, Braghetta P, Vuagniaux G, Dumont JM, Baldari CT, Bonaldo P, Bernardi P: **The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1-/- myopathic mice.** *British Journal of Pharmacology* 2009, **157**:1045-1052.
114. Erb M, Meinen S, Barzaghi P, Sumanovski LT, Courdier-Fruh I, Ruegg MA, Meier T: **Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-(alpha)2 deficiency.** *J Pharmacol Exp Ther* 2009, **331**:787-795.
115. Zingman LV, Park S, Olson TM, Alekseev AE, Terzic A: **Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy.** *Clin Pharmacol Ther* 2007, **81**:99-103.

doi:10.1186/2044-5040-1-30

**Cite this article as:** Allamand et al.: ColVI myopathies: where do we stand, where do we go? *Skeletal Muscle* 2011 1:30.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

